Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Amy C. Degnim
- Target Recruit Count
- 104
- Registration Number
- NCT04570956
- Locations
- 🇺🇸
MD Anderson Cancer center at Cooper, Camden, New Jersey, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Jennifer Lee Caswell-Jin
- Target Recruit Count
- 4
- Registration Number
- NCT04504331
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Instituto Jalisciense de Cancerologia
- Target Recruit Count
- 300
- Registration Number
- NCT04389424
- Locations
- 🇲🇽
Instituto Jalisciense de Cancerologia, Guadalajara, Jalisco, Mexico
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 69
- Registration Number
- NCT04300790
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Hospital Universitario de Leon, León, Spain
🇪🇸Hospital Beata María Ana, Madrid, Spain
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 1
- Registration Number
- NCT04190056
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT04174352
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Wisconsin Oncology Network (WONIX) sites, Madison, Wisconsin, United States
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 42
- Registration Number
- NCT04079517
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 367
- Registration Number
- NCT04059484
- Locations
- 🇺🇦
Investigational Site Number : 8040001, Kryvyi Rih, Ukraine
🇬🇷Investigational Site Number : 3000004, Thessaloniki, Greece
🇧🇷Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03879577
- Locations
- 🇳🇬
University College Hospital, Ibadan, Nigeria, Ibadan, Nigeria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.